This is the first study to determine whether the study medication has a positive benefit for subjects on their ulcerative colitis symptom control, as well as effects on inflammatory marker cytokines (plasma tumour necrosis factor [TNF]α, interleukin [IL]-2, IL-6), C reactive protein [CRP], faecal inflammatory marker (calprotectin), stool frequency (NRS), rectal bleeding (NRS), pain (NRS). In addition, various IBD questionnaires are being implemented in the study to observe further benefits on the study medication, compared with placebo.